Bleeding, Cancer-associated Thrombosis, Recurrence, Rivaroxaban
Conditions
Brief summary
Rivaroxaban has been developed in the various clinical settings, prevention of venous thromboembolism (VTE)after major orthopedic surgery, prevention of stroke in atrial fibrillation, and in the treatment of acute coronary syndromes. And, in the EINSTEIN-pulmonary embolism (PE) and EINSTEIN-deep venous thrombosis (DVT) programs, rivaroxaban showed non-inferior to standard therapy for the treatment of PE and DVT. However, there has been limited experience of rivaroxaban with secondary VTE prophylaxis in cancer patients. Although cancer-associated DVT or PE was included in previously mentioned EINSTEIN programs, only approximately 5% of the total populations were cancer patients in these studies. Thus, investigators could not automatically translate the results of these studies into the real practice management of cancer-associated VTE patients. Moreover, until now, new oral anticoagulants, including dabigatran and rivaroxaban, have been compared to long-term warfarin therapy, which were well-known inferior agent, but not low molecular weight heparin. In this sense, investigators feel that new oral anticoagulants, particularly rivaroxaban, should be re-investigated in this highly specific patients group. Therefore, investigators are planning to conduct a prospective study evaluating the efficacy and safety of rivaroxaban in Korean patients with cancer-associated VTE.
Interventions
DRUGRivaroxaban
Rivaroxaban 15mg twice daily for the first 3 weeks, followed by 20mg once daily during 6 months
Sponsors
Korean Society of Hematology Thrombosis Working Party
Seoul National University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients ≥ 20 years old and active cancer and newly-diagnosed, symptomatic or incidental proximal lower extremity DVT, PE or both * will have a life expectancy \> 3 months * will be treated with anticoagulation therapy for at least 3 months.
Exclusion criteria
* (1) Isolated asymptomatic distal DVT * (2) Intra-abdominal venous thrombosis or vascular access-induced thrombosis * (3) Hemodynamically unstable PE, indicating systolic blood pressure \<90 mmHg * (4)Eastern Cooperative Oncology Group (ECOG) performance status score of 3 or 4 * (5) History of total gastrectomy * (6) Overt brain metastasis. Patients who have controlled brain metastasis without need of glucocorticoid are eligible * (7) History of recent major or clinically relevant bleeding within the previous 4 weeks * (8) Conditions associated with a high risk of serious bleeding (active peptic ulcer or recent neurosurgery) * (9) Other serious illness or medical conditions (illnesses requiring chronic anticoagulation therapy, unstable cardiac disease despite treatment, myocardial infarction within 3 months prior to study entry, significant neurologic or psychiatric diseases including dementia or seizure, active uncontrolled infection, other serious medical conditions) * (10)Inadequate renal function; creatinine clearance \< 30 ml/min * (11) Inadequate hepatic function: alanine aminotransferase \> 3 times the upper limit of normal (ULN) (if liver metastasis, alanine aminotransferase \> 5 times the ULN or total bilirubin \>2 times the ULN (if liver metastasis, total bilirubin \>3 times the ULN) * (12) Baseline platelet count \< 75,000 per cubic millimeter or Hb \< 8g/dL * (13) Plan of treatment with bevacizumab or other anti-cancer drugs known to increase the bleeding risk * (14) Women of childbearing potential who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for the entire study period, who are using a prohibited contraceptive method, or who are pregnant or breastfeeding * (15) Patients requiring strong cytochrome P450 3A4 (CYP3A4) inducers (rifampin, phenobarbital) or strong CYP3A4 inhibitors (HIV protease inhibitor, systemic ketoconazole) treatments * (16) Patients with inferior vena cava filter placement or underwent catheter-directed thrombolysis or stent placement for the treatment of index VTE
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| recurrent symptomatic deep venous thrombosis, pulmonary embolism or both | within the six months after the diagnosis of index VTE | Recurrent DVT will be defined if a new onset non-compressibility of a previously compressible venous segment on ultrasonography is identified or if there is a new constant intraluminal filling defect on venography. Unequivocal extension of the thrombus will be needed to diagnose the recurrence on the same extremity of the first event unless new concomitant PE or DVT in other extremities is confirmed. Recurrent PE will be diagnosed by high probability on ventilation/perfusion lung scan, or by the presence of non-enhancing filling defects in the pulmonary vasculature on pulmonary CT angiogram. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| incidentally detected VTE | within six months after the diagnosis of VTE | Incidentally detected recurrent thrombosis will be defined as objectively-proven thrombosis during the study period by imaging studies that are performed for reasons other than suspected VTE. |
| Major or clinically relevant non-major bleedings | within six months after the diagnosis of VTE | Major bleeding will be defined if it is associated with death, occurs at critical sites (intracranial, intraspinal, intraocular, retroperitoneal, or pericardial area), and results in a need for a transfusion of at least 2 units of packed red cells, or lead to a drop in hemoglobin of more than 2 g/dL. Clinically relevant non-major bleeding will be defined as relevant bleeding that did not meet the criteria for major bleeding but is associated with medical intervention, unscheduled visit, interruption or discontinuation of a study drug, or discomfort or impairment of activities of daily life |
| recurrent VTE according to the risk of clinical prediction rule | within six months after the diagnosis of VTE | Risk of recurrent VTE can be differentiated by risk prediction rule, named Ottawa score. Ottawa score is composed of gender, primary tumor site, stage, and prior VTE and ranged between -3 and 3 score points. Patients with a score \<1 will be considered as having low risk for recurrence and patients with a score \>1 considered as having high risk for recurrence. |
Countries
South Korea
Outcome results
None listed